<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Duchenne and Becker muscular dystrophy: Glucocorticoid and disease-modifying treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Duchenne and Becker muscular dystrophy: Glucocorticoid and disease-modifying treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Duchenne and Becker muscular dystrophy: Glucocorticoid and disease-modifying treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Basil T Darras, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H59379875"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in a number of genes required for normal muscle function [<a href="#rid1">1</a>]. The Duchenne and Becker muscular dystrophies are caused by pathogenic variants of the dystrophin (<em>DMD</em>) gene and are therefore named dystrophinopathies. Weakness is the principal symptom as muscle fiber degeneration is the primary pathologic process.</p><p>The dystrophinopathies are inherited as X-linked recessive traits and have varying clinical characteristics. Duchenne muscular dystrophy (DMD) is associated with the most severe clinical symptoms. Becker muscular dystrophy (BMD) has a similar presentation to DMD but a relatively milder clinical course [<a href="#rid2">2</a>].</p><p>Glucocorticoid treatment and potential disease-modifying therapies for Duchenne muscular dystrophy will be discussed in this review. Other aspects of Duchenne and Becker muscular dystrophy are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/116654.html" rel="external">"Duchenne and Becker muscular dystrophy: Genetics and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/6149.html" rel="external">"Duchenne and Becker muscular dystrophy: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6181.html" rel="external">"Duchenne and Becker muscular dystrophy: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H997077185"><span class="h1">GLUCOCORTICOID TREATMENT</span><span class="headingEndMark"> — </span>Glucocorticoids are the mainstay of pharmacologic treatment for DMD [<a href="#rid2">2-6</a>].</p><p class="headingAnchor" id="H3623635557"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Glucocorticoids are indicated for children with DMD and should be started before there is substantial physical decline  (<a class="graphic graphic_figure graphicRef116911" href="/z/d/graphic/116911.html" rel="external">figure 1</a>) [<a href="#rid6">6</a>]. For children with DMD age four years or older whose motor skills have plateaued or have started to decline, we suggest daily treatment with glucocorticoids using either oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a>, or <a class="drug drug_general" data-topicid="143213" href="/z/d/drug information/143213.html" rel="external">vamorolone</a> (where available). (See <a class="local">'Benefits of glucocorticoid therapy'</a> below.)</p><p>We generally prefer <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> because it offers a more favorable side effect profile than <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> regarding weight gain and impact on behavior. Although deflazacort is more likely to cause growth slowing than prednisone, there is some evidence that shorter stature offers a biomechanical advantage in DMD and is associated with slower disease progression [<a href="#rid7">7,8</a>]. In a retrospective study of 70 patients with DMD, those who lost ambulation at a later age had significantly shorter stature than those who lost ambulation earlier [<a href="#rid9">9</a>]. However, insurance coverage for deflazacort in the United States is sometimes limited due to its higher cost. (See <a class="local">'Adverse effects and monitoring'</a> below.)</p><p><a class="drug drug_general" data-topicid="143213" href="/z/d/drug information/143213.html" rel="external">Vamorolone</a> is a novel steroid designed to avoid or reduce the adverse effects of glucocorticoid therapy. It acts as a dissociative glucocorticoid ligand to exert anti-inflammatory and immunosuppressive effects. Like <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, vamorolone inhibits the NF-kB pathway, but its chemical structure lacks the glucocorticoid receptor binding elements (eg, the 11b-hydroxyl/carbonyl group) believed to be responsible for some of prednisone's side effects. While glucocorticoids are agonists, vamorolone acts as a potent mineralocorticoid antagonist, which prevents negative mineralocorticoid effects [<a href="#rid10">10</a>]. Vamorolone received FDA approval in late 2023 for the treatment of DMD in patients two years of age and older [<a href="#rid11">11</a>]; availability is expected in early 2024.</p><p class="headingAnchor" id="H92368616"><span class="h2">Glucocorticoid dosing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prednisone</strong> – The usual starting dose of oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for treating DMD is 0.75 mg/kg per day [<a href="#rid6">6</a>]. Less well-studied alternative prednisone dosing regimens include 5 mg/kg per day given two times per week on consecutive weekend days or 0.75 mg/kg per day for 10 days on and 10 days off [<a href="#rid2">2,12,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deflazacort</strong> – The usual starting dose of oral <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> is 0.9 mg/kg per day [<a href="#rid6">6</a>]. Deflazacort is an oxazoline derivative of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>; the relative potency of prednisone compared with deflazacort is 1:1.3 [<a href="#rid14">14</a>]. Thus, 1.3 mg of deflazacort is approximately equivalent to 1 mg of prednisone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vamorolone</strong> – The recommended dose of oral <a class="drug drug_general" data-topicid="143213" href="/z/d/drug information/143213.html" rel="external">vamorolone</a> is 6 mg/kg per day with meals (maximum dose 300 mg for patients who weigh &gt;50 kg) [<a href="#rid15">15</a>]. For patients with mild or moderate hepatic impairment, the recommended dose of vamorolone is 2 mg/kg per day with meals (maximum dose 100 mg for patients who weigh &gt;50 kg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjustments for patient weight gain during growth</strong> – Although practice is variable, many clinicians do not make weight-based dose adjustments of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> as patient weight increases over time [<a href="#rid16">16</a>], and the DMD care guidelines do not mandate such adjustments in the absence of functional decline [<a href="#rid6">6</a>]. This strategy may reduce the risk of adverse effects.</p><p></p><p class="bulletIndent1">The author ordinarily does not make dose adjustments with weight gain unless the patient is rapidly declining, or until the <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose is 0.3 to 0.4 mg/kg per day or the <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> dose is 0.4 to 0.5 mg/kg per day. In these situations, it is reasonable to increase the glucocorticoid dose to the starting weight-based target dose (prednisone 0.75 mg/kg per day or deflazacort 0.9 mg/kg per day).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose reduction for intolerable adverse effects</strong> – Maintaining the glucocorticoid dose is optimal if side effects are tolerable and manageable. The glucocorticoid dose can be reduced by 25 to 33 percent if the adverse effects are intolerable or unmanageable, with reassessment in one month [<a href="#rid6">6</a>]. The dose can be lowered by an additional 25 percent if intolerable adverse effects persist. A gradual tapering of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> to as low as 0.3 mg/kg per day or <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> to as low as 0.4 mg/kg per day may give significant but less robust benefit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid rapid withdrawal</strong> – In patients on long-term glucocorticoid therapy, abrupt cessation or rapid withdrawal of glucocorticoids should be avoided because it can result in adrenal insufficiency (see <a class="local">'Glucocorticoid tapering'</a> below). In the setting of acute illness, trauma, or surgery, stress-dose glucocorticoid therapy may be needed. (See  <a class="medical medical_review" href="/z/d/html/6181.html" rel="external">"Duchenne and Becker muscular dystrophy: Management and prognosis", section on 'Adrenal insufficiency'</a> and <a class="local">'Indications for stress-dose glucocorticoids'</a> below.)</p><p></p><p class="headingAnchor" id="H1704210574"><span class="h2">Benefits of glucocorticoid therapy</span><span class="headingEndMark"> — </span>Glucocorticoid treatment of DMD with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> and <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> is beneficial for improving motor function, strength, and pulmonary function; reducing the risk of scoliosis; and delaying the loss of ambulation [<a href="#rid4">4,6</a>]. In addition, some data suggest that glucocorticoids improve survival and delay the onset of cardiomyopathy. The mechanism of the beneficial effect of glucocorticoids in patients with DMD is not clear. Little is known of the effect of glucocorticoids in patients with Becker muscular dystrophy (BMD).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Motor function</strong> – In several small, randomized trials, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> treatment led to increased average muscle strength and improvement in standardized timed function testing (eg, time to climb stairs, walk nine meters, or arise from supine to standing). As an example, a six-month trial of 103 boys with DMD found that average muscle strength increased by 11 percent with prednisone treatment compared with placebo. In addition, the average time to climb four stairs was approximately 43 percent faster with prednisone treatment compared with placebo (four versus seven seconds, respectively). In this and other trials, strength increased significantly by 10 days, reached a maximum at three months, and was maintained at six months and 18 months [<a href="#rid17">17-19</a>].</p><p></p><p class="bulletIndent1">In a trial of 28 patients with DMD, <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> treatment for nine months was associated with increased muscle strength and function compared with placebo [<a href="#rid20">20</a>]. Other studies found that deflazacort was associated with improvement in various measures of motor function or delay in loss of ambulation [<a href="#rid20">20-25</a>]. The mean prolongation of ambulation was 13 months [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">In the multicenter VISION-DMD trial, 121 ambulatory and glucocorticoid-naive male patients (ages four to less than seven years) with DMD were randomly assigned in a 1:1:1:1 ratio to <a class="drug drug_general" data-topicid="143213" href="/z/d/drug information/143213.html" rel="external">vamorolone</a> 6 mg/kg per day, vamorolone 2 mg/kg per day, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.75 mg/kg per day, or placebo [<a href="#rid26">26</a>]. At 24 weeks compared with placebo, high-dose vamorolone treatment (6 mg/kg per day) led to improvement on the Time to Stand Test (TTSTAND) velocity (least-squares mean [LSM] 0.06 meters/second; 95% CI 0.02-0.1 meters/second), the 6-Minute Walk Test (6MWT) distance (LSM 41.6 meters; 95% CI 14.2-68.9 meters), and the Time to Run/Walk 10 meters (TTRW) velocity (LSM 0.24 meters/second; 95% CI 0.09-0.39 meters/second). Compared with placebo, low-dose vamorolone (2 mg/kg per day) showed significant improvement on TTSTAND velocity and 6MWT distance but not TTRW velocity. The differences in TTSTAND velocity and 6MWT distance for vamorolone (both doses) compared with placebo were considered clinically meaningful [<a href="#rid26">26-28</a>].</p><p></p><p class="bulletIndent1">The duration of most of these studies ranged from 6 to 18 months. One longer-term prospective observational study with up to 10 years of follow-up enrolled 440 males 2 to 28 years of age with DMD [<a href="#rid29">29</a>]. Compared with glucocorticoid treatment for one month or less, glucocorticoid treatment for one year or longer was associated with a delay in disease progression, including an increased median age at loss of mobility milestones (by 2.1 to 4.4 years) and upper limb milestones (by 2.8 to 8 years).</p><p></p><p class="bulletIndent1">Our clinical experience also supports the benefit of glucocorticoids. When patients are taken off glucocorticoids because of adverse effects, clinicians, families, and/or caregivers usually notice a decline in motor function and energy level, particularly in younger patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary function</strong> – Several small trials and nonrandomized studies have found that glucocorticoids improve pulmonary function in patients with DMD [<a href="#rid4">4,17,18,23-25,30-33</a>]. As an example, in one trial of 103 boys with DMD, forced vital capacity (FVC) improved significantly (11 percent higher) after six months of daily <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> treatment compared with placebo [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Orthopedic outcomes</strong> – Glucocorticoids may delay the development of scoliosis and reduce the need for surgery to correct scoliosis in patients with DMD [<a href="#rid4">4</a>]. In a prospective nonrandomized study of boys with DMD who were followed for 15 years, the risk of developing scoliosis was significantly lower for the daily <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> treatment group compared with the control group (6 of 30 [20 percent] versus 22 of 24 [92 percent]), and the need for spine surgery was also significantly decreased for the deflazacort group [<a href="#rid30">30</a>]. Retrospective data also suggest that long-term therapy with glucocorticoids for DMD reduces the risk of scoliosis and prolongs independent ambulation but increases the risk of osteoporosis and long bone and vertebral compression fractures [<a href="#rid34">34</a>]. However, in a prospective international registry of 340 male subjects with DMD, there were few fractures, and fracture prevalence was similar between patients who were treated with glucocorticoids and those who were not [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">Measures for assessing and maintaining bone health are described below. (See  <a class="medical medical_review" href="/z/d/html/6181.html" rel="external">"Duchenne and Becker muscular dystrophy: Management and prognosis", section on 'Bone health'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Survival</strong> – In a 2016 systematic review of glucocorticoid treatment of DMD [<a href="#rid4">4</a>], three studies found that glucocorticoid treatment was associated with improved survival [<a href="#rid24">24,30,35</a>], while a fourth found no clear association with length of survival [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac function</strong> – Data from several nonrandomized studies suggest that treatment with glucocorticoids for DMD reduces new-onset and progressive cardiomyopathy and lowers mortality via a reduction in deaths related to heart failure [<a href="#rid35">35-38</a>]. These findings require confirmation in larger prospective trials.</p><p></p><p class="headingAnchor" id="H2474715809"><span class="h2">Studies comparing agents</span><span class="headingEndMark"> — </span>In most reports, the efficacy of <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> for DMD is similar to that of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid4">4,39-43</a>]. These studies reported comparable improvements in muscle function, pulmonary function, and orthopedic outcomes with prednisone and deflazacort treatment.</p><p>The Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR-DMD) trial investigated the three most commonly prescribed glucocorticoid regimens and randomly assigned 196 boys with DMD in a 1:1:1 ratio to daily <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (0.75 mg/kg), daily <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> (0.90 mg/kg), or intermittent prednisone (0.75 mg/kg, alternating 10 days on and 10 days off) [<a href="#rid43">43</a>]. Over three years, the efficacy of daily prednisone and daily deflazacort was similar on a composite outcome that incorporated measures of motor function (rising from the floor velocity), pulmonary function (FVC), and satisfaction with treatment. Both daily regimens were more effective than intermittent prednisone, a difference that was mainly attributable to the rising from the floor velocity component of the composite outcome; the difference in rising from the floor velocity for daily prednisone versus intermittent prednisone was 0.06 rise/second (98.3% CI 0.03-0.08) and for daily deflazacort versus intermittent prednisone was 0.06 rise/second (98.3% CI 0.03-0.09); these were considered clinically important differences. The daily prednisone and daily deflazacort groups were similar for rising from the floor velocity (-0.004 rise/second, 98.3% CI -0.03 to 0.02) and for FVC and treatment satisfaction. In addition, the daily prednisone and daily deflazacort regimens showed similar effectiveness and were more effective than intermittent prednisone for all secondary motor outcomes.</p><p>In the FOR-DMD trial, weight gain was greater with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (daily or intermittent) compared with daily <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> [<a href="#rid43">43</a>]. More slowing of growth occurred with daily deflazacort compared with daily prednisone, while both daily regimens led to more slowing of growth compared with intermittent prednisone.</p><p>In the VISION-DMD trial, the relative efficacy of <a class="drug drug_general" data-topicid="143213" href="/z/d/drug information/143213.html" rel="external">vamorolone</a> 6 mg/kg per day was similar to that of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.75 mg/kg per day for all motor outcomes [<a href="#rid26">26</a>].</p><p>Two meta-analyses comparing <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> versus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>/<a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> in patients with <em>DMD</em> nonsense or other pathogenic variants who received placebo in multicenter trials of ataluren and <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> found that the deflazacort-treated patients exhibited less decline in a series of motor function outcomes over a period of 48 weeks [<a href="#rid44">44,45</a>]. Nevertheless, these studies are limited by the nonrandomized assignment of glucocorticoid treatment. Limited observational data suggest that deflazacort is associated with a lower rate of aggressive behaviors [<a href="#rid29">29,46</a>].</p><p class="headingAnchor" id="H2684626588"><span class="h2">Adverse effects and monitoring</span><span class="headingEndMark"> — </span>The most common adverse effects after 6 to 36 months of treatment with daily glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a>) for boys with DMD are weight gain, decreased linear growth and short stature, hirsutism, and cushingoid appearance [<a href="#rid4">4,17,18,43</a>]. Other adverse effects of glucocorticoids include delayed puberty, long bone and vertebral bone fractures, acne, gastrointestinal symptoms, cataracts, and behavioral changes.</p><p>Therefore, growth, endocrine, bone health surveillance, and periodic eye examinations for cataracts are recommended in DMD patients treated with glucocorticoids. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Monitoring and treatment of adverse effects'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight gain</strong> – <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> may cause greater weight gain than <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a>. Thus, deflazacort is used in preference to prednisone for patients with DMD who may be predisposed to obesity based on body habitus, dietary habits, or family history. In the FOR-DMD trial, weight gain was greater with prednisone (daily or intermittent) compared with daily deflazacort [<a href="#rid43">43</a>]. The difference in weight gain for the daily prednisone compared with the daily deflazacort group was 2.6 kg (98.3% CI 0.2-5.0 kg) and for daily deflazacort compared with intermittent prednisone was -3.1 kg (98.3% CI -5.5 to -0.7 kg). In an earlier randomized controlled trial of 196 boys with DMD, subjects assigned to prednisone (0.75 mg/kg per day) had greater mean weight gain at 12 and 52 weeks compared with subjects assigned to either of two deflazacort doses (0.9 and 1.2 mg/kg per day) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1">Weight gain in patients with DMD is an undesirable side effect that may accelerate loss of ambulation, which in turn will lead to more weight gain unless dietary measures are taken to adjust caloric intake. If weight gain is excessive, an obesity management plan should be devised that addresses both diet and physical activity. (See  <a class="medical medical_review" href="/z/d/html/5861.html" rel="external">"Clinical evaluation of the child or adolescent with obesity"</a> and  <a class="medical medical_review" href="/z/d/html/15848.html" rel="external">"Prevention and management of childhood obesity in the primary care setting"</a>.)</p><p></p><p class="bulletIndent1">If obesity management is not successful, the glucocorticoid dose can be lowered by 20 to 25 percent, and/or patients on <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> can be switched to <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> (but excessive weight gain can sometimes occur on deflazacort). If these measures fail and weight gain is unacceptable for the child or family/caregivers, glucocorticoids can be tapered off. (See <a class="local">'Glucocorticoid tapering'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Slowing of growth</strong> – In the FOR-DMD trial, there was more slowing of growth with daily <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> compared with daily <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>; the difference in height at three years for daily prednisone versus daily deflazacort was 2.3 cm (98.3% CI 0.7-3.9 cm) [<a href="#rid43">43</a>]. Both daily regimens led to more slowing of growth than intermittent prednisone; the difference for daily deflazacort compared with intermittent prednisone was -8.1 cm (98.3% CI -9.7 to -6.4 cm), while the difference for daily prednisone compared with intermittent prednisone was -5.8 cm (98.3% CI -7.4 to -4.2 cm).</p><p></p><p class="bulletIndent1">In the VISION-DMD trial, height percentile compared with baseline declined at 24 weeks with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> treatment (-1.88) and increased with <a class="drug drug_general" data-topicid="143213" href="/z/d/drug information/143213.html" rel="external">vamorolone</a> 6 mg/kg day treatment (+3.86); the difference was statistically significant [<a href="#rid26">26</a>]. Earlier open-label extension studies found that vamorolone treatment was associated with normal growth velocity over 18 months [<a href="#rid47">47</a>] and 30 months [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventive measures for bone loss</strong> – We suggest preventive measures to minimize bone loss for patients with DMD who are receiving prolonged glucocorticoid therapy. Such measures include dietary calcium and vitamin D supplementation, and yearly dual-energy x-ray absorptiometry (DXA) scanning and a 25-hydroxyvitamin D level. (See  <a class="medical medical_review" href="/z/d/html/6181.html" rel="external">"Duchenne and Becker muscular dystrophy: Management and prognosis", section on 'Bone health'</a>.)</p><p></p><p>In the 24-week VISION-DMD trial, serum biomarkers of bone formation (osteocalcin, procollagen 1 intact N-terminal propeptide [P1NP]) and bone turnover (type 1 collagen cross-linked C-telopeptide [CTX1]) declined from baseline with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> treatment but not with <a class="drug drug_general" data-topicid="143213" href="/z/d/drug information/143213.html" rel="external">vamorolone</a> [<a href="#rid26">26</a>]. </p><p class="headingAnchor" id="H1821374322"><span class="h2">Indications for stress-dose glucocorticoids</span><span class="headingEndMark"> — </span>In the setting of severe illness, major trauma, or surgery, most patients taking <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> dose &gt;12 mg/m<sup>2</sup> of body surface area per day will require stress-dose glucocorticoids (<a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> 50 to 100 mg/m<sup>2</sup> per day) to prevent acute adrenal insufficiency [<a href="#rid6">6</a>]. Note that the stress doses for glucocorticoids are based upon body surface area, while the DMD treatment doses for prednisone and deflazacort are based upon weight. (See  <a class="medical medical_review" href="/z/d/html/6181.html" rel="external">"Duchenne and Becker muscular dystrophy: Management and prognosis", section on 'Adrenal insufficiency'</a>.)</p><p class="headingAnchor" id="H2285681327"><span class="h2">Duration of glucocorticoid therapy</span><span class="headingEndMark"> — </span>In the absence of significant obesity or other intolerable side effects, glucocorticoids should be continued even for patients who become nonambulatory because treatment may slow or delay the development of scoliosis, pulmonary function decline, and heart failure. Thus, treatment is lifelong in the absence of major adverse effects. Examples of potential reasons for tapering off glucocorticoid therapy include vertebral fractures, development of severe obesity, or recurrent pulmonary infections (if immunosuppression is a concern).</p><p class="headingAnchor" id="H2017035987"><span class="h2">Glucocorticoid tapering</span><span class="headingEndMark"> — </span>Glucocorticoids should not be stopped abruptly. This is particularly important for patients with a suppressed hypothalamic-pituitary-adrenal (HPA) axis. Expert guidelines recommend implementation of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.parentprojectmd.org%2Fwp-content%2Fuploads%2F2018%2F03%2FPJ-Nicholoff-Steroid-Protocol.pdf&amp;token=Ns%2F09NX%2FS%2Bo1IBVlcGf5W1mNX4QoTZF5W%2F0tlRue98FeczINtPip9pF%2Btv%2BfWSriBNCd0HoVuIj%2F5%2F1430%2BCZ8BGybgrbjaZvqb6yXLs7c8OZjEqYghIAyHNGnrJELhF&amp;TOPIC_ID=116918" target="_blank">PJ Nicholoff tapering protocol</a> [<a href="#rid49">49</a>] for patients who wish to discontinue glucocorticoid therapy [<a href="#rid6">6</a>]. The full protocol is available online; the main steps are as follows [<a href="#rid49">49</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Decrease the glucocorticoid dose by 20 to 25 percent every two weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Once a physiologic dose is achieved (3 mg/m<sup>2</sup> per day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a>), switch to <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> 12 mg/m<sup>2</sup> daily divided into three equal doses</p><p class="bulletIndent1"><span class="glyph">●</span>Continue to decrease the glucocorticoid dose by 20 to 25 percent every week until achieving a dose of 2.5 mg <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> every other day</p><p class="bulletIndent1"><span class="glyph">●</span>After two weeks of dosing every other day, stop <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a></p><p class="bulletIndent1"><span class="glyph">●</span>Periodically check morning adrenocorticotropic hormone (ACTH)-stimulated cortisol concentration until the HPA axis is normal</p><p></p><p>Patients who have surgery or develop serious illness or injury during the taper may require stress-dose glucocorticoids (see <a class="local">'Indications for stress-dose glucocorticoids'</a> above) until the HPA axis has recovered, a process that may take 12 months or longer [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H4007909118"><span class="h1">GENETIC THERAPIES</span><span class="headingEndMark"> — </span>Genetic therapies that involve exon skipping (<a class="drug drug_general" data-topicid="109946" href="/z/d/drug information/109946.html" rel="external">eteplirsen</a>, <a class="drug drug_general" data-topicid="126392" href="/z/d/drug information/126392.html" rel="external">golodirsen</a>, <a class="drug drug_general" data-topicid="129261" href="/z/d/drug information/129261.html" rel="external">viltolarsen</a>), read-through of premature termination codon (ataluren), or microdystrophin transgenes delivered by adeno-associated virus (AAV) vectors (<a class="drug drug_general" data-topicid="141855" href="/z/d/drug information/141855.html" rel="external">delandistrogene moxeparvovec</a>) are approved in some countries for the treatment of DMD. These therapies increase dystrophin expression  (<a class="graphic graphic_figure graphicRef143463" href="/z/d/graphic/143463.html" rel="external">figure 2</a>), but clinical benefit has not been established [<a href="#rid50">50,51</a>].</p><p class="headingAnchor" id="H1319691784"><span class="h2">Shared decision-making</span><span class="headingEndMark"> — </span>While the available genetic therapies for DMD may increase dystrophin levels, it is uncertain if patients benefit from treatment. Nevertheless, some families or guardians of patients with amenable pathogenic gene variants and their clinicians may reasonably choose one of these treatments based upon the potential (but uncertain) benefit and despite the known risks and extraordinary high cost of treatment. Shared decision-making must include discussions of what is known and what is uncertain regarding benefits, risks, burdens, and costs of these therapies.</p><p class="headingAnchor" id="H2398234217"><span class="h2">Exon skipping</span><span class="headingEndMark"> — </span>Injection of antisense oligonucleotides that induce specific exon skipping during messenger ribonucleic acid (RNA) splicing are designed to correct the open reading frame of the <em>DMD</em> gene in patients with out-of-frame deletions or duplications and thereby restore dystrophin expression  (<a class="graphic graphic_figure graphicRef143463" href="/z/d/graphic/143463.html" rel="external">figure 2</a>) [<a href="#rid2">2</a>]. Results from small clinical studies in humans suggest the promise of this approach, including those evaluating <a class="drug drug_general" data-topicid="109946" href="/z/d/drug information/109946.html" rel="external">eteplirsen</a>, <a class="drug drug_general" data-topicid="126392" href="/z/d/drug information/126392.html" rel="external">golodirsen</a>, <a class="drug drug_general" data-topicid="129261" href="/z/d/drug information/129261.html" rel="external">viltolarsen</a>, and <a class="drug drug_general" data-topicid="130888" href="/z/d/drug information/130888.html" rel="external">casimersen</a>.</p><p class="headingAnchor" id="H735674698"><span class="h3">Eteplirsen</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="109946" href="/z/d/drug information/109946.html" rel="external">Eteplirsen</a> is an antisense oligonucleotide designed to skip exon 51 of the <em>DMD</em> gene.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – <a class="drug drug_general" data-topicid="109946" href="/z/d/drug information/109946.html" rel="external">Eteplirsen</a> may be used to treat children with DMD who have exon 51 amenable pathogenic variants. These deletion variants are present in approximately 13 percent of patients with DMD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – An open-label study of 19 patients with DMD and eligible <em>DMD</em> deletion variants found that weekly intravenous administration of <a class="drug drug_general" data-topicid="109946" href="/z/d/drug information/109946.html" rel="external">eteplirsen</a> induced a dose-related increase in dystrophin production without drug-related adverse effects [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1">A subsequent 24-week placebo-controlled trial randomly assigned 12 patients (ages 7 to 13 years and ambulatory) in a 1:1:1 ratio to weekly dosing of intravenous <a class="drug drug_general" data-topicid="109946" href="/z/d/drug information/109946.html" rel="external">eteplirsen</a> 30 mg/kg, eteplirsen 50 mg/kg, or placebo [<a href="#rid53">53</a>]. This was followed by a 24-week open-label extension phase during which all subjects received eteplirsen. At 48 weeks, those assigned to eteplirsen 50 mg/kg walked a greater distance in the six-minute walk test compared with the placebo/delayed eteplirsen group. However, two patients assigned to eteplirsen 30 mg/kg lost ambulation during the trial. At 24 weeks, muscle biopsy revealed that patients assigned to eteplirsen 30 mg/kg had an increase in dystrophin-positive fibers of 23 percent compared with no increase in the placebo group, and the difference was statistically significant. (Muscle biopsy was not done at 24 weeks for the eteplirsen 50 mg/kg group.) At 48 weeks, the increase in dystrophin-positive fibers for the eteplirsen 30 mg/kg and 50 mg/kg groups was 52 and 43 percent, respectively. Through week 48, there were no adverse events related to eteplirsen treatment. Findings from an open-label extension phase of the study through 36 months suggested that, compared with historical controls, eteplirsen-treated patients had continued benefit on the six-minute walk test and a lower rate of loss of ambulation [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1">Another report, with data from three studies of eteplirsen-treated ambulatory (n = 54) and primarily nonambulatory (n = 20) patients with DMD, found that <a class="drug drug_general" data-topicid="109946" href="/z/d/drug information/109946.html" rel="external">eteplirsen</a> treatment was associated with a statistically significant and clinically meaningful attenuated annual decline in percent predicted forced vital capacity (FVC%p) values when compared with historical glucocorticoid-treated control patients with DMD [<a href="#rid55">55</a>]. This result supports the use of eteplirsen in nonambulatory DMD patients.</p><p></p><p class="bulletIndent1">Based upon the finding of increased dystrophin in skeletal muscle observed in patients treated with <a class="drug drug_general" data-topicid="109946" href="/z/d/drug information/109946.html" rel="external">eteplirsen</a>, the US Food and Drug Administration (FDA) granted accelerated approval of eteplirsen in September 2016 for the treatment of patients with DMD who have a confirmed deletion of the <em>DMD</em> gene amenable to exon 51 skipping [<a href="#rid51">51,56</a>]. The FDA approval of eteplirsen was based on a surrogate outcome (dystrophin increase in muscle biopsy) [<a href="#rid57">57</a>]. As part of the accelerated approval process, the prescribing label states that "continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials" [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The recommended dose of <a class="drug drug_general" data-topicid="109946" href="/z/d/drug information/109946.html" rel="external">eteplirsen</a> is 30 mg/kg once a week by intravenous infusion over 35 to 60 minutes [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – In small clinical studies, the most common adverse reactions were balance disorder, vomiting, contact dermatitis, contusion, excoriation, arthralgia, rash, catheter site pain, and upper respiratory tract infection [<a href="#rid52">52-54,58</a>]. Hypersensitivity reactions have occurred, including bronchospasm, chest pain, cough, tachycardia, and urticaria [<a href="#rid58">58</a>].</p><p></p><p class="headingAnchor" id="H3904075129"><span class="h3">Golodirsen</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126392" href="/z/d/drug information/126392.html" rel="external">Golodirsen</a> is an antisense oligonucleotide that is designed to modify the splicing of exon 53 of dystrophin pre-messenger RNA, resulting in exon 53 skipping of the <em>DMD</em> gene.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – <a class="drug drug_general" data-topicid="126392" href="/z/d/drug information/126392.html" rel="external">Golodirsen</a> may be used to treat children with DMD who have amenable exon 53 pathogenic variants in the <em>DMD</em> gene. The frequency of this variant among patients with DMD is estimated to be 8 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In a preliminary trial, 12 children with DMD who had confirmed <em>DMD</em> pathogenic variants amenable to exon 53 skipping were assigned in a 2:1 ratio to weekly intravenous infusions of <a class="drug drug_general" data-topicid="126392" href="/z/d/drug information/126392.html" rel="external">golodirsen</a> or placebo; this was followed by an open-label study of golodirsen that included the original 12 patients from the randomized trial plus an additional 13 treatment-naïve patients with DMD amenable to exon 53 skipping [<a href="#rid59">59</a>]. The median age of patients at study entry was eight years. After 48 weeks or more of treatment, the mean dystrophin level increased from 0.1 percent of normal at baseline to 1.02 percent of normal. Clinical benefit was not reported. The FDA is requiring the manufacturer to show that golodirsen has clinical benefit (ie, improved motor function) in an ongoing trial [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1">Based upon the surrogate outcome of increased dystrophin production, the FDA granted accelerated approval of <a class="drug drug_general" data-topicid="126392" href="/z/d/drug information/126392.html" rel="external">golodirsen</a> in December 2019 for the treatment of patients with DMD who have a confirmed deletion pathogenic variant of the dystrophin gene amenable to exon 53 skipping [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration </strong>– The recommended dose of <a class="drug drug_general" data-topicid="126392" href="/z/d/drug information/126392.html" rel="external">golodirsen</a> is 30 mg/kg once a week by intravenous infusion over 35 to 60 minutes [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1">Urine dipstick, serum cystatin C, and urine protein-to-creatinine ratio should be measured before starting <a class="drug drug_general" data-topicid="126392" href="/z/d/drug information/126392.html" rel="external">golodirsen</a> and monitored during treatment, checking urine dipstick every month and serum cystatin C and urine protein-to-creatinine ratio every three months. The glomerular filtration rate should also be measured before starting golodirsen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most frequent adverse reactions associated with <a class="drug drug_general" data-topicid="126392" href="/z/d/drug information/126392.html" rel="external">golodirsen</a> in clinical studies were headache, fever, cough, vomiting, abdominal pain, nasopharyngitis, and nausea. Hypersensitivity reactions have also been observed, including rash, fever, itching, hives, dermatitis, and skin exfoliation. Renal toxicity has been observed with other antisense oligonucleotides.</p><p></p><p class="headingAnchor" id="H960307212"><span class="h3">Viltolarsen</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="129261" href="/z/d/drug information/129261.html" rel="external">Viltolarsen</a> is an antisense oligonucleotide that is designed to bind to exon 53 of dystrophin pre-messenger RNA, resulting in exon 53 skipping during messenger RNA splicing in patients.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – <a class="drug drug_general" data-topicid="129261" href="/z/d/drug information/129261.html" rel="external">Viltolarsen</a> may be used to treat patients with amenable exon 53 nonsense variants of the <em>DMD</em> gene; this type of pathogenic variant is present in an estimated 8 percent of patients with DMD [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – A dose-finding safety trial enrolled 16 boys with <em>DMD</em> gene deletions amenable to exon 53 skipping who were randomly assigned in a 3:1 ratio to intravenous <a class="drug drug_general" data-topicid="129261" href="/z/d/drug information/129261.html" rel="external">viltolarsen</a> or placebo for four weeks, followed by a 20-week open-label treatment period [<a href="#rid63">63</a>]. Patients assigned to viltolarsen 80 mg/kg once a week showed an increase in dystrophin from a mean level of 0.6 percent of normal at baseline to 5.9 percent of normal at week 25. Among secondary outcomes, all 16 subjects showed improvement on timed function tests compared with historical controls. Continued FDA approval may depend upon confirmation of clinical benefit in further trials.</p><p></p><p class="bulletIndent1">Based upon the surrogate outcome of increased dystrophin production, the FDA granted accelerated approval of <a class="drug drug_general" data-topicid="129261" href="/z/d/drug information/129261.html" rel="external">viltolarsen</a> in August 2020 for the treatment of patients with DMD who have a confirmed deletion of the dystrophin gene amenable to exon 53 skipping [<a href="#rid62">62</a>]. In Japan, viltolarsen was approved in March 2020 [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – The recommended dose of <a class="drug drug_general" data-topicid="129261" href="/z/d/drug information/129261.html" rel="external">viltolarsen</a> is 80 mg/kg once a week, given by intravenous infusion over 60 minutes [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">Urine dipstick, serum cystatin C, and urine protein-to-creatinine ratio should be measured before starting <a class="drug drug_general" data-topicid="129261" href="/z/d/drug information/129261.html" rel="external">viltolarsen</a>, and measuring the glomerular filtration rate should also be considered prior to treatment. The label recommends monitoring for kidney toxicity during treatment by checking urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio every three months. Only urine free of excreted viltolarsen should be used for monitoring urine protein; therefore, urine samples should be obtained at least 48 hours after the most recent infusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse reactions with <a class="drug drug_general" data-topicid="129261" href="/z/d/drug information/129261.html" rel="external">viltolarsen</a> were upper respiratory tract infections, injection site reactions, cough, and pyrexia. Renal toxicity has been observed with other antisense oligonucleotides.</p><p></p><p class="headingAnchor" id="H3793218548"><span class="h3">Casimersen</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="130888" href="/z/d/drug information/130888.html" rel="external">Casimersen</a> is an antisense oligonucleotide that is designed to bind to exon 45 of dystrophin pre-messenger RNA, resulting in exon 45 skipping during messenger RNA processing in patients with amenable deletion pathogenic variants of the <em>DMD</em> gene.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – <a class="drug drug_general" data-topicid="130888" href="/z/d/drug information/130888.html" rel="external">Casimersen</a> may be used to treat patients who have a confirmed pathogenic variant of <em>DMD</em> that is amenable to exon 45 skipping, which causes approximately 8 percent of DMD cases [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – <a class="drug drug_general" data-topicid="130888" href="/z/d/drug information/130888.html" rel="external">Casimersen</a> treatment increased dystrophin production, as shown in an interim analysis of 43 patients (ages 7 to 20 years) with a deletion in <em>DMD</em> amenable to exon 45 skipping who were randomly assigned in a 2:1 ratio to treatment with casimersen or placebo [<a href="#rid66">66</a>]. At 48 weeks, the mean increase in dystrophin levels from baseline on muscle biopsy for patients assigned to casimersen was 0.81 percent, compared with 0.22 percent for the placebo group [<a href="#rid67">67</a>]. Clinical benefit was not reported in this preliminary analysis. Continued FDA approval may depend upon confirmation of clinical benefit in further trials. Based upon the surrogate outcome of increased dystrophin production, the FDA granted accelerated approval of casimersen in February 2021 for the treatment of patients with DMD and an amenable exon 45 pathogenic variant [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The dose of <a class="drug drug_general" data-topicid="130888" href="/z/d/drug information/130888.html" rel="external">casimersen</a> is 30 mg/kg once weekly given by intravenous infusion over 35 to 60 minutes using an in-line 0.2 micron filter [<a href="#rid67">67</a>]. Laboratory studies to include serum cystatin C, urine protein-to-creatinine ratio, and urine dipstick should be measured before starting casimersen and monitored during treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most frequent adverse reactions in clinical trials were respiratory tract infections, cough, fever, headache, joint pain, and oropharyngeal pain [<a href="#rid67">67</a>]. Hypersensitivity reactions, including angioedema and anaphylaxis, have occurred in postmarketing experience. Use is <strong>contraindicated</strong> in patients with known hypersensitivity to <a class="drug drug_general" data-topicid="130888" href="/z/d/drug information/130888.html" rel="external">casimersen</a>. Hypersensitivity reactions should be managed with appropriate medical treatment in addition to stopping the infusions.</p><p></p><p class="headingAnchor" id="H3152073672"><span class="h2">Stop codon read-through</span><span class="headingEndMark"> — </span>Some patients with DMD/Becker muscular dystrophy (BMD) harbor a nonsense (stop) pathogenic variant that leads to a premature termination codon (PTC) in the messenger RNA and causes a disruption of dystrophin translation [<a href="#rid68">68</a>]. The strategy of stop codon read-through employs small molecules that promote messenger RNA translation through the PTC to generate a functional protein  (<a class="graphic graphic_figure graphicRef143463" href="/z/d/graphic/143463.html" rel="external">figure 2</a>). This approach could benefit the estimated 10 to 15 percent of patients with DMD/BMD who harbor nonsense (stop) pathogenic variants [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H1729339538"><span class="h3">Ataluren</span><span class="headingEndMark"> — </span>Ataluren (PTC124) is an orally administered drug being developed for the treatment of genetic defects caused by pathogenic nonsense (stop) variants. Ataluren promotes ribosomal read-through of nonsense (stop) pathogenic variants, allowing bypass of the nonsense variant and continuation of the translation process to production of a functioning protein.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – Where licensed (eg, the European Union and United Kingdom), ataluren is an option to treat patients ages two years and older with DMD caused by nonsense pathogenic variants. This approach could benefit the estimated 10 to 15 percent of patients with DMD who harbor nonsense (stop) variants [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The clinical benefit of ataluren is not yet established.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a phase 2 study of 26 boys with nonsense variant-mediated DMD, increased full-length dystrophin expression was observed in vitro and in vivo with PTC124, and serum muscle enzyme levels decreased within 28 days of treatment [<a href="#rid70">70</a>]. However, there were only minimal changes in muscle strength and timed functions with PTC124 treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A multicenter double-blind trial randomly assigned 174 ambulatory males (median age eight years, range 5 to 20) with DMD/BMD to high-dose ataluren, low-dose ataluren, or placebo [<a href="#rid71">71</a>]. At 48 weeks, the mean decline in the six-minute walk distance was approximately 30 meters less for the low-dose ataluren group compared with the placebo group. However, the mean change in the six-minute walk distance for the high-dose ataluren group was similar to that for placebo group. Based on the low-dose ataluren group results, ataluren received conditional approval by the European Commission in August 2014 to treat DMD caused by a nonsense pathogenic variant in the dystrophin gene. Ataluren is available to patients in 23 countries through either expanded access programs or commercial sales, but it is not approved for treating DMD in the United States.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a phase 3, multicenter, 48-week, blinded, placebo-controlled trial (Ataluren Confirmatory Trial in Duchenne Muscular Dystrophy [ACT DMD]) of 228 boys with nonsense variant-mediated DMD, there was <strong>no</strong> significant benefit of ataluren for the primary endpoint, change from baseline in the six-minute walk test, though there was benefit for some secondary endpoints [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – Ataluren, available in sachets as granules, is administered orally by mixing it into a suspension with liquid or semisolid food [<a href="#rid73">73</a>]. The recommended dose is 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening, for a total daily dose of 40 mg/kg. Recommended dosing intervals are six hours between morning and midday doses, six hours between midday and evening doses, and 12 hours between the evening dose and the first dose on the following day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse effect of ataluren is vomiting [<a href="#rid73">73</a>]. Others include decreased appetite, weight loss, hypertriglyceridemia, headache, hypertension, cough, epistaxis, nausea, upper abdominal pain, flatulence, abdominal discomfort, constipation, rash, limb pain, musculoskeletal chest pain, hematuria, enuresis, and pyrexia.</p><p></p><p class="headingAnchor" id="H3074228651"><span class="h2">Gene transfer via viral vectors</span><span class="headingEndMark"> — </span>The large size of the <em>DMD</em> gene (2.4 Mb) prevents its packaging into AAV vectors, which can only accommodate up to 4.7 kb genes. The case of a 61-year-old ambulatory patient with BMD and a large deletion of exons 17 to 48 (approximately 46 percent of the <em>DMD</em> gene) led to the design of microdystrophin transgenes, which maintain some of the critical domains of the dystrophin gene and protein  (<a class="graphic graphic_figure graphicRef143463" href="/z/d/graphic/143463.html" rel="external">figure 2</a>) [<a href="#rid74">74</a>]. Results from small trials evaluating <a class="drug drug_general" data-topicid="141855" href="/z/d/drug information/141855.html" rel="external">delandistrogene moxeparvovec</a> suggest the potential benefit of this approach. (See <a class="local">'Delandistrogene moxeparvovec'</a> below.)</p><p>Several earlier studies in mice used a gene-correction strategy employing AAV vectors to deliver the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 genome engineering system, which cuts the noncoding introns that flank exon 23 [<a href="#rid75">75-78</a>]. This method partially restored dystrophin protein expression in cardiac and skeletal muscle and was associated with enhanced muscle function.</p><p class="headingAnchor" id="H1407340505"><span class="h3">Delandistrogene moxeparvovec</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="141855" href="/z/d/drug information/141855.html" rel="external">Delandistrogene moxeparvovec</a> is an adeno-associated virus capsid (AAVrh74) containing a transgene encoding a microdystrophin protein under the control of a muscle-specific MHCK7 promoter; it is designed to deliver the microdystrophin transgene to skeletal and cardiac muscles [<a href="#rid79">79,80</a>]. Although it produces microdystrophin protein, the clinical benefit of delandistrogene moxeparvovec is not established.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection </strong>– <a class="drug drug_general" data-topicid="141855" href="/z/d/drug information/141855.html" rel="external">Delandistrogene moxeparvovec</a> was approved in the United States by the FDA in June 2023 for the treatment of ambulatory boys with DMD, ages four through five years, who have a proven pathogenic variant in the <em>DMD</em> gene [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – FDA approval was based in part upon the surrogate outcome of increased microdystrophin production demonstrated in two small trials; microdystrophin protein expression measured by Western blot of muscle biopsies was significantly increased compared with baseline after 12 weeks of treatment [<a href="#rid81">81,82</a>]. In one trial (n = 41), there was no improvement in functional outcome as measured by the mean change from baseline to week 48 in the North Star Ambulatory Assessment (NSAA), a 17-item rating scale of functional motor abilities in ambulatory children with DMD [<a href="#rid83">83</a>]. The mean change in NSAA score for the <a class="drug drug_general" data-topicid="141855" href="/z/d/drug information/141855.html" rel="external">delandistrogene moxeparvovec</a> group compared with the placebo group (1.7 versus 0.9) was not statistically significant. In a subgroup analysis, there was a greater improvement in the mean change from baseline in the NSAA score for children in the four- to five-year age group assigned to delandistrogene moxeparvovec compared with placebo (4.3 versus 1.9), while there was no difference between groups for children in the six- to seven-year age group (-0.2 versus 0.5) [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – <a class="drug drug_general" data-topicid="141855" href="/z/d/drug information/141855.html" rel="external">Delandistrogene moxeparvovec</a> is given as a single intravenous infusion. The recommended dose is 1.33 × 10<sup>14</sup> vector genomes/kg of body weight (10 mL/kg body weight) given over one to two hours and infused at a rate of &lt;10 mL/kg per hour [<a href="#rid82">82</a>]. Treatment should be postponed in patients with active infection until the infection has resolved. Testing for liver function, platelet count, troponin-I level, and anti-AAVrh74 antibodies should be done before starting the medication. Glucocorticoid treatment (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, maximum 60 mg daily) is recommended starting one day prior to the infusion and continuing for at least 60 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse effects of <a class="drug drug_general" data-topicid="141855" href="/z/d/drug information/141855.html" rel="external">delandistrogene moxeparvovec</a> are vomiting, nausea, increased levels of hepatic enzymes and bilirubin, pyrexia, and thrombocytopenia [<a href="#rid82">82</a>]. Warnings and precautions include serious liver injury, immune-mediated myositis, and myocarditis. Delandistrogene moxeparvovec is contraindicated for patients with a deletion in exon 8 and/or exon 9 of the <em>DMD</em> gene, as these patients are at increased risk for severe immune-mediated myositis.</p><p></p><p class="bulletIndent1">Patients with <em>DMD</em> gene deletions involving exons 1 to 17 and/or exons 59 to 71 could also be at risk for severe immune-mediated myositis; along with glucocorticoids, additional immunosuppressants (eg, a calcineurin inhibitor) may be considered if symptoms of myositis occur [<a href="#rid82">82</a>].</p><p></p><p class="headingAnchor" id="H2499992789"><span class="h3">Risk of immune reactions with AAV vectors</span><span class="headingEndMark"> — </span>The use of recombinant adeno-associated virus (rAAV) vectors to deliver gene therapy is associated with a risk of severe or fatal immune and inflammatory reactions [<a href="#rid84">84-86</a>]. Potent immune responses may be induced because high doses of rAAV are needed to deliver sufficient gene therapy to the sizeable amount of muscle tissue in the body. This risk is illustrated by a report of a 27-year-old patient with advanced DMD and impaired cardiopulmonary function who was treated with high-dose rAAV serotype 9 containing a CRISPR-based transgene designed to upregulate dystrophin [<a href="#rid86">86</a>]. The patient developed worsening cardiac dysfunction a few days after treatment, followed by acute respiratory distress syndrome (ARDS), cardiac arrest, and death on day eight. Evidence from laboratory and postmortem studies suggested that the death was due to an innate immune reaction triggered by the high load of rAAV. Further research to develop safer approaches [<a href="#rid87">87</a>] and identify high-risk patients may help to mitigate the acute toxic effects of rAAV gene therapy. (See  <a class="medical medical_review" href="/z/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Potential concerns with gene therapy'</a>.)</p><p class="headingAnchor" id="H3079925301"><span class="h1">OTHER INVESTIGATIONAL THERAPIES</span><span class="headingEndMark"> — </span>Other potential approaches for treating DMD include creatine, myostatin inactivation, and skeletal muscle progenitors [<a href="#rid50">50</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Creatine</strong> – Creatine monohydrate has been studied for its potential to increase muscle strength in neuromuscular disorders and muscular dystrophies, but data are limited and suggest that creatine treatment leads only to modest benefit at best [<a href="#rid87">87-91</a>]. Demonstration of clinically important improvement in larger trials is needed before recommending this treatment for patients with DMD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myostatin inactivation</strong> – Myostatin is a protein that has an inhibitory effect on muscle growth. Mice that would otherwise express the DMD phenotype but lack myostatin have an increased muscle mass compared with those with a wildtype myostatin gene [<a href="#rid92">92</a>]. Antibodies to myostatin also have a beneficial effect; treated animals have increased muscle mass, strength, lower serum creatine kinase, and less histologic evidence of muscle damage [<a href="#rid93">93</a>]. A myostatin variant was identified in a child with gross muscle hypertrophy [<a href="#rid94">94</a>], suggesting that myostatin inactivation could be a therapeutic target to increase muscle bulk and strength in muscle-wasting diseases such as DMD [<a href="#rid95">95</a>]. However, preliminary trials of myostatin inhibitors in muscular dystrophy have not yet demonstrated clinical benefit [<a href="#rid96">96-98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell therapy</strong> – Treatment with allogeneic cardiosphere-derived cells (CDCs), derived from cardiac progenitor cells, has shown promise for treating DMD; the proposed mechanism is a disease-modifying anti-inflammatory effect [<a href="#rid99">99,100</a>]. The placebo-controlled HOPE-2 trial was stopped early due to funding problems, but in data available for 20 patients with DMD, intravenous administration of CDCs (every three months for four infusions) led to a reduced rate of disease progression at 12 months as measured by a decline from baseline in an upper limb strength score (Performance of Upper Limb [PUL] motor function) of 0.8 points for the treated group and 3.4 points for the placebo group [<a href="#rid101">101</a>]. The between-group difference of 2.6 points was felt to be clinically meaningful. Three patients developed hypersensitivity reactions with infusion of CDCs. Study limitations include small patient numbers and lack of long-term follow-up; larger and longer trials are needed to confirm efficacy.</p><p></p><p class="bulletIndent1">The use of skeletal muscle progenitors in the treatment of DMD and BMD remains experimental [<a href="#rid102">102-108</a>].</p><p></p><p class="headingAnchor" id="H1235828287"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/121073.html" rel="external">"Society guideline links: Muscular dystrophy"</a>.)</p><p class="headingAnchor" id="H3411948572"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – For children with Duchenne muscular dystrophy (DMD) age four years or older whose motor skills have plateaued or declined, we suggest glucocorticoid treatment with <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, or <a class="drug drug_general" data-topicid="143213" href="/z/d/drug information/143213.html" rel="external">vamorolone</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We generally prefer deflazacort because it offers a more favorable side effect profile than prednisone regarding weight gain and impact on behavior. Treatment with prednisone, deflazacort, or vamorolone may improve motor function, strength, and pulmonary function; reduce the risk of scoliosis; and possibly delay the onset of cardiomyopathy. (See <a class="local">'Glucocorticoid treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dose</strong> – The usual starting dose of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for treating DMD is 0.75 mg/kg per day. The usual starting dose of <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> is 0.9 mg/kg per day. The recommended dose of oral <a class="drug drug_general" data-topicid="143213" href="/z/d/drug information/143213.html" rel="external">vamorolone</a> is 6 mg/kg per day with meals (maximum dose 300 mg for patients weighing ≥50 kg).</p><p></p><p class="bulletIndent2">Although practice is variable, the dose of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> is generally not adjusted for weight as patient weight increases over time in the absence of functional decline; this strategy may reduce the risk of adverse effects. (See <a class="local">'Glucocorticoid dosing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adverse effects </strong>– The most common side effects of treatment with glucocorticoids for DMD are weight gain, slowing of growth, hirsutism, and cushingoid appearance. Limited evidence suggests that <a class="drug drug_general" data-topicid="111930" href="/z/d/drug information/111930.html" rel="external">deflazacort</a> treatment is associated with an increased risk of cataracts and a decreased risk of weight gain compared with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>. Limited evidence also suggests that <a class="drug drug_general" data-topicid="143213" href="/z/d/drug information/143213.html" rel="external">vamorolone</a> treatment reduces the risk of slowing of growth compared with prednisone. (See <a class="local">'Adverse effects and monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration</strong> – Treatment with glucocorticoids is lifelong in the absence of major adverse effects. (See <a class="local">'Duration of glucocorticoid therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic therapies</strong> – Genetic therapies that involve exon skipping (<a class="drug drug_general" data-topicid="109946" href="/z/d/drug information/109946.html" rel="external">eteplirsen</a>, <a class="drug drug_general" data-topicid="126392" href="/z/d/drug information/126392.html" rel="external">golodirsen</a>, <a class="drug drug_general" data-topicid="129261" href="/z/d/drug information/129261.html" rel="external">viltolarsen</a>), stop codon read-through (ataluren), or microdystrophin transgene delivery by an adeno-associated virus vector (<a class="drug drug_general" data-topicid="141855" href="/z/d/drug information/141855.html" rel="external">delandistrogene moxeparvovec</a>) are approved in some countries for the treatment of DMD  (<a class="graphic graphic_figure graphicRef143463" href="/z/d/graphic/143463.html" rel="external">figure 2</a>). (See <a class="local">'Genetic therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Shared decision-making</strong> – While these therapies may modestly increase dystrophin levels, it is uncertain if patients benefit from treatment. Nevertheless, some families or guardians of patients with amenable pathogenic gene variants and their clinicians may reasonably choose one of these treatments based upon the potential but uncertain benefit, despite the known risks, burdens, and extraordinarily high cost of treatment. Shared decision-making must include discussions of these issues. (See <a class="local">'Shared decision-making'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patient selection</strong> – Where available, disease-modifying treatments for DMD are:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="130888" href="/z/d/drug information/130888.html" rel="external">Casimersen</a>, for patients with a confirmed pathogenic variant in the <em>DMD </em>gene amenable to exon 45 skipping (see <a class="local">'Casimersen'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="109946" href="/z/d/drug information/109946.html" rel="external">Eteplirsen</a>, for patients with a confirmed pathogenic variant in the <em>DMD </em>gene amenable to exon 51 skipping (see <a class="local">'Eteplirsen'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="126392" href="/z/d/drug information/126392.html" rel="external">Golodirsen</a> and <a class="drug drug_general" data-topicid="129261" href="/z/d/drug information/129261.html" rel="external">viltolarsen</a>, for patients with a confirmed pathogenic variant in th<em>e DMD </em>gene amenable to exon 53 skipping (see <a class="local">'Golodirsen'</a> above and <a class="local">'Viltolarsen'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Ataluren, for patients with a nonsense (stop) <em>DMD</em> pathogenic variant that produces a premature termination codon (PTC) in the messenger RNA (see <a class="local">'Ataluren'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="141855" href="/z/d/drug information/141855.html" rel="external">Delandistrogene moxeparvovec</a>, for ambulatory boys ages four through five years who have a proven (nonspecific) pathogenic variant in the <em>DMD </em>gene (see <a class="local">'Delandistrogene moxeparvovec'</a> above)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Emery AE. The muscular dystrophies. Lancet 2002; 359:687.</a></li><li><a class="nounderline abstract_t">Lee BH. The Dystrophinopathies. Continuum (Minneap Minn) 2022; 28:1678.</a></li><li><a class="nounderline abstract_t">Wein N, Alfano L, Flanigan KM. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. Pediatr Clin North Am 2015; 62:723.</a></li><li><a class="nounderline abstract_t">Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016; 86:465.</a></li><li><a class="nounderline abstract_t">Matthews E, Brassington R, Kuntzer T, et al. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev 2016; :CD003725.</a></li><li><a class="nounderline abstract_t">Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018; 17:251.</a></li><li><a class="nounderline abstract_t">Zatz M, Rapaport D, Vainzof M, et al. Relation between height and clinical course in Duchenne muscular dystrophy. Am J Med Genet 1988; 29:405.</a></li><li><a class="nounderline abstract_t">Bodor M, McDonald CM. Why short stature is beneficial in Duchenne muscular dystrophy. Muscle Nerve 2013; 48:336.</a></li><li><a class="nounderline abstract_t">Labove L, Jaworski M, Nguyen C-TE. Duchenne muscular dystrophy: Do boys with a shorter stature maintain ambulation longer? J Neuromuscul Dis 2018; 5:S142.</a></li><li><a class="nounderline abstract_t">Heier CR, Yu Q, Fiorillo AA, et al. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance 2019; 2.</a></li><li class="breakAll">Muscular Dystrophy Association-supported drug Agamree (vamorolone) approved for the treatment of Duchenne muscular dystrophy by the FDA. Available at: https://www.mda.org/press-releases/mda-supported-drug-agamree-vamorolone-approved-for-the-treatment-of-duchenne-muscular-dystrophy-by-the-fda (Accessed on December 07, 2023).</li><li><a class="nounderline abstract_t">Escolar DM, Hache LP, Clemens PR, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011; 77:444.</a></li><li><a class="nounderline abstract_t">Bello L, Gordish-Dressman H, Morgenroth LP, et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology 2015; 85:1048.</a></li><li><a class="nounderline abstract_t">Parente L. Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol 2017; 18:1.</a></li><li class="breakAll">Agamree (vamorolone) oral suspencsion prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215239s000lbl.pdf (Accessed on December 07, 2023).</li><li><a class="nounderline abstract_t">Biggar WD, Skalsky A, McDonald CM. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy. J Neuromuscul Dis 2022; 9:463.</a></li><li><a class="nounderline abstract_t">Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989; 320:1592.</a></li><li><a class="nounderline abstract_t">Griggs RC, Moxley RT 3rd, Mendell JR, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991; 48:383.</a></li><li><a class="nounderline abstract_t">Griggs RC, Moxley RT 3rd, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993; 43:520.</a></li><li><a class="nounderline abstract_t">Mesa LE, Dubrovsky AL, Corderi J, et al. Steroids in Duchenne muscular dystrophy--deflazacort trial. Neuromuscul Disord 1991; 1:261.</a></li><li><a class="nounderline abstract_t">Angelini C, Pegoraro E, Turella E, et al. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 1994; 17:386.</a></li><li><a class="nounderline abstract_t">Biggar WD, Politano L, Harris VA, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord 2004; 14:476.</a></li><li><a class="nounderline abstract_t">Biggar WD, Gingras M, Fehlings DL, et al. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 2001; 138:45.</a></li><li><a class="nounderline abstract_t">Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006; 16:249.</a></li><li><a class="nounderline abstract_t">Alman BA, Raza SN, Biggar WD. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy. J Bone Joint Surg Am 2004; 86-A:519.</a></li><li><a class="nounderline abstract_t">Guglieri M, Clemens PR, Perlman SJ, et al. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA Neurol 2022; 79:1005.</a></li><li><a class="nounderline abstract_t">Duong T, Canbek J, Birkmeier M, et al. The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD. J Neuromuscul Dis 2021; 8:939.</a></li><li><a class="nounderline abstract_t">McDonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 2013; 48:357.</a></li><li><a class="nounderline abstract_t">McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 2018; 391:451.</a></li><li><a class="nounderline abstract_t">Lebel DE, Corston JA, McAdam LC, et al. Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. J Bone Joint Surg Am 2013; 95:1057.</a></li><li><a class="nounderline abstract_t">Henricson EK, Abresch RT, Cnaan A, et al. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 2013; 48:55.</a></li><li><a class="nounderline abstract_t">Bach JR, Martinez D, Saulat B. Duchenne muscular dystrophy: the effect of glucocorticoids on ventilator use and ambulation. Am J Phys Med Rehabil 2010; 89:620.</a></li><li><a class="nounderline abstract_t">Daftary AS, Crisanti M, Kalra M, et al. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics 2007; 119:e320.</a></li><li><a class="nounderline abstract_t">King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007; 68:1607.</a></li><li><a class="nounderline abstract_t">Schram G, Fournier A, Leduc H, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol 2013; 61:948.</a></li><li><a class="nounderline abstract_t">Markham LW, Kinnett K, Wong BL, et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 2008; 18:365.</a></li><li><a class="nounderline abstract_t">Houde S, Filiatrault M, Fournier A, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008; 38:200.</a></li><li><a class="nounderline abstract_t">Barber BJ, Andrews JG, Lu Z, et al. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr 2013; 163:1080.</a></li><li><a class="nounderline abstract_t">Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000; 23:1344.</a></li><li><a class="nounderline abstract_t">Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 2005; 84:843.</a></li><li><a class="nounderline abstract_t">Markham LW, Spicer RL, Khoury PR, et al. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 2005; 26:768.</a></li><li><a class="nounderline abstract_t">Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology 2016; 87:2123.</a></li><li><a class="nounderline abstract_t">Guglieri M, Bushby K, McDermott MP, et al. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA 2022; 327:1456.</a></li><li><a class="nounderline abstract_t">McDonald CM, Sajeev G, Yao Z, et al. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve 2020; 61:26.</a></li><li><a class="nounderline abstract_t">Shieh PB, Elfring G, Trifillis P, et al. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res 2021; 10:1337.</a></li><li><a class="nounderline abstract_t">Sienko S, Buckon C, Fowler E, et al. Prednisone and Deflazacort in Duchenne Muscular Dystrophy: Do They Play a Different Role in Child Behavior and Perceived Quality of Life? PLoS Curr 2016; 8.</a></li><li><a class="nounderline abstract_t">Smith EC, Conklin LS, Hoffman EP, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. PLoS Med 2020; 17:e1003222.</a></li><li><a class="nounderline abstract_t">Mah JK, Clemens PR, Guglieri M, et al. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. JAMA Netw Open 2022; 5:e2144178.</a></li><li><a class="nounderline abstract_t">Kinnett K, Noritz G. The PJ Nicholoff Steroid Protocol for Duchenne and Becker Muscular Dystrophy and Adrenal Suppression. PLoS Curr 2017; 9.</a></li><li><a class="nounderline abstract_t">Markati T, Oskoui M, Farrar MA, et al. Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol 2022; 21:814.</a></li><li><a class="nounderline abstract_t">Bendicksen L, Zuckerman DM, Avorn J, et al. The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence. Ann Intern Med 2023; 176:1251.</a></li><li><a class="nounderline abstract_t">Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378:595.</a></li><li><a class="nounderline abstract_t">Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013; 74:637.</a></li><li><a class="nounderline abstract_t">Mendell JR, Goemans N, Lowes LP, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 2016; 79:257.</a></li><li><a class="nounderline abstract_t">Khan N, Eliopoulos H, Han L, et al. Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy. J Neuromuscul Dis 2019; 6:213.</a></li><li class="breakAll">FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. U.S. Food &amp; Drug Administration. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm521263.htm (Accessed on September 22, 2016).</li><li><a class="nounderline abstract_t">Kesselheim AS, Avorn J. Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy. JAMA 2016; 316:2357.</a></li><li class="breakAll">EXONDYS 51 (eteplirsen) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206488s027s028s029lbl.pdf (Accessed on January 26, 2022).</li><li><a class="nounderline abstract_t">Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology 2020; 94:e2270.</a></li><li class="breakAll">FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation (Accessed on December 17, 2019).</li><li class="breakAll">Vyondys 53 (golodirsen) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211970s002lbl.pdf (Accessed on March 07, 2021).</li><li class="breakAll">FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation. https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation (Accessed on August 19, 2020).</li><li><a class="nounderline abstract_t">Clemens PR, Rao VK, Connolly AM, et al. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. JAMA Neurol 2020; 77:982.</a></li><li><a class="nounderline abstract_t">Dhillon S. Viltolarsen: First Approval. Drugs 2020; 80:1027.</a></li><li class="breakAll">Viltepso (viltolarsen) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212154s002lbl.pdf (Accessed on March 15, 2021).</li><li class="breakAll">U.S. Food &amp; Drug Administration, 2021. FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation-0 (Accessed on February 26, 2021).</li><li class="breakAll">Amondys 45 (casimersen) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213026s005lbl.pdf (Accessed on May 17, 2023).</li><li><a class="nounderline abstract_t">Bez Batti Angulski A, Hosny N, Cohen H, et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front Physiol 2023; 14:1183101.</a></li><li><a class="nounderline abstract_t">Finkel RS. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 2010; 25:1158.</a></li><li><a class="nounderline abstract_t">Bönnemann C, Finkel R, Wong B, et al. Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy. Neuromuscul Disord 2007; 17:783.</a></li><li><a class="nounderline abstract_t">Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014; 50:477.</a></li><li><a class="nounderline abstract_t">McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390:1489.</a></li><li class="breakAll">Translarna: EPAR - Product information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002720/WC500171813.pdf (Accessed on March 27, 2018).</li><li><a class="nounderline abstract_t">England SB, Nicholson LV, Johnson MA, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990; 343:180.</a></li><li><a class="nounderline abstract_t">Long C, Amoasii L, Mireault AA, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 2016; 351:400.</a></li><li><a class="nounderline abstract_t">Nelson CE, Hakim CH, Ousterout DG, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 2016; 351:403.</a></li><li><a class="nounderline abstract_t">Tabebordbar M, Zhu K, Cheng JK, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 2016; 351:407.</a></li><li><a class="nounderline abstract_t">Calos MP. The CRISPR Way to Think about Duchenne's. N Engl J Med 2016; 374:1684.</a></li><li><a class="nounderline abstract_t">Mendell JR, Sahenk Z, Lehman K, et al. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol 2020; 77:1122.</a></li><li><a class="nounderline abstract_t">Potter RA, Griffin DA, Heller KN, et al. Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy. Hum Gene Ther 2021; 32:375.</a></li><li><a class="nounderline abstract_t">Hoy SM. Delandistrogene Moxeparvovec: First Approval. Drugs 2023; 83:1323.</a></li><li class="breakAll">Elevidys (delandistrogene moxeparvovec-rokl) suspension, for intravenous infusion. https://www.fda.gov/media/169679/download (Accessed on August 28, 2023).</li><li><a class="nounderline abstract_t">Mendell JR, Shieh PB, McDonald CM, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol 2023; 11:1167762.</a></li><li><a class="nounderline abstract_t">Kumar SRP, Duan D, Herzog RW. Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies. Hum Gene Ther 2023; 34:365.</a></li><li><a class="nounderline abstract_t">Lek A, Atas E, Hesterlee SE, et al. Meeting Report: 2022 Muscular Dystrophy Association Summit on 'Safety and Challenges in Gene Transfer Therapy'. J Neuromuscul Dis 2023; 10:327.</a></li><li><a class="nounderline abstract_t">Lek A, Wong B, Keeler A, et al. Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy. N Engl J Med 2023; 389:1203.</a></li><li><a class="nounderline abstract_t">Louis M, Lebacq J, Poortmans JR, et al. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve 2003; 27:604.</a></li><li><a class="nounderline abstract_t">Walter MC, Lochmüller H, Reilich P, et al. Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study. Neurology 2000; 54:1848.</a></li><li><a class="nounderline abstract_t">Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst Rev 2013; :CD004760.</a></li><li><a class="nounderline abstract_t">Tarnopolsky MA, Mahoney DJ, Vajsar J, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004; 62:1771.</a></li><li><a class="nounderline abstract_t">Escolar DM, Buyse G, Henricson E, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 2005; 58:151.</a></li><li><a class="nounderline abstract_t">Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002; 52:832.</a></li><li><a class="nounderline abstract_t">Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420:418.</a></li><li><a class="nounderline abstract_t">Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004; 350:2682.</a></li><li><a class="nounderline abstract_t">McNally EM. Powerful genes--myostatin regulation of human muscle mass. N Engl J Med 2004; 350:2642.</a></li><li><a class="nounderline abstract_t">Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008; 63:561.</a></li><li><a class="nounderline abstract_t">Campbell C, McMillan HJ, Mah JK, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve 2017; 55:458.</a></li><li><a class="nounderline abstract_t">Wagner KR. The elusive promise of myostatin inhibition for muscular dystrophy. Curr Opin Neurol 2020; 33:621.</a></li><li><a class="nounderline abstract_t">Aminzadeh MA, Rogers RG, Fournier M, et al. Exosome-Mediated Benefits of Cell Therapy in Mouse and Human Models of Duchenne Muscular Dystrophy. Stem Cell Reports 2018; 10:942.</a></li><li><a class="nounderline abstract_t">Rogers RG, Fournier M, Sanchez L, et al. Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice. JCI Insight 2019; 4.</a></li><li><a class="nounderline abstract_t">McDonald CM, Marbán E, Hendrix S, et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2022; 399:1049.</a></li><li><a class="nounderline abstract_t">Gussoni E, Blau HM, Kunkel LM. The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 1997; 3:970.</a></li><li><a class="nounderline abstract_t">Gussoni E, Bennett RR, Muskiewicz KR, et al. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. J Clin Invest 2002; 110:807.</a></li><li><a class="nounderline abstract_t">Gussoni E, Soneoka Y, Strickland CD, et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999; 401:390.</a></li><li><a class="nounderline abstract_t">Skuk D, Roy B, Goulet M, et al. Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. Mol Ther 2004; 9:475.</a></li><li><a class="nounderline abstract_t">Cerletti M, Jurga S, Witczak CA, et al. Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell 2008; 134:37.</a></li><li><a class="nounderline abstract_t">Blau HM. Cell therapies for muscular dystrophy. N Engl J Med 2008; 359:1403.</a></li><li><a class="nounderline abstract_t">Zhao M, Tazumi A, Takayama S, et al. Induced Fetal Human Muscle Stem Cells with High Therapeutic Potential in a Mouse Muscular Dystrophy Model. Stem Cell Reports 2020; 15:80.</a></li></ol></div><div id="topicVersionRevision">Topic 116918 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11879882" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The muscular dystrophies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36537975" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Dystrophinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26022172" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26833937" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27149418" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Corticosteroids for the treatment of Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29395989" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3354613" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Relation between height and clinical course in Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23893308" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Why short stature is beneficial in Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Duchenne muscular dystrophy: Do boys with a shorter stature maintain ambulation longer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30745312" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30745312" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21753160" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26311750" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28057083" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28057083" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35723111" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2657428" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2012511" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8450994" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1822804" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Steroids in Duchenne muscular dystrophy--deflazacort trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8170484" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Deflazacort in Duchenne dystrophy: study of long-term effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15336688" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148511" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Deflazacort treatment of Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16545568" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996877" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36036925" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34151852" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23674289" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29174484" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23783200" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23649481" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647779" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Duchenne muscular dystrophy: the effect of glucocorticoids on ventilator use and ambulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17272595" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485648" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352781" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436445" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18279756" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23866715" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10951436" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16244521" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15990951" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Steroid therapy and cardiac function in Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27566742" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35381069" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31599456" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34693725" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27525172" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prednisone and Deflazacort in Duchenne Muscular Dystrophy: Do They Play a Different Role in Child Behavior and Perceived Quality of Life?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32956407" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35076703" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28744411" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The PJ Nicholoff Steroid Protocol for Duchenne and Becker Muscular Dystrophy and Adrenal Suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35850122" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Emerging therapies for Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37603868" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784508" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23907995" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Eteplirsen for the treatment of Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26573217" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30856119" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30856119" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27775756" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27775756" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139505" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139505" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139505" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139505" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32453377" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32519222" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Viltolarsen: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32519222" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Viltolarsen: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32519222" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Viltolarsen: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32519222" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Viltolarsen: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37435300" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Duchenne muscular dystrophy: disease mechanism and therapeutic strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20519671" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25042182" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Ataluren treatment of patients with nonsense mutation dystrophinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28728956" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28728956" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2404210" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Very mild muscular dystrophy associated with the deletion of 46% of dystrophin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26721683" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26721684" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26721686" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : In vivo gene editing in dystrophic mouse muscle and muscle stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27119241" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The CRISPR Way to Think about Duchenne's.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32539076" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33397205" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37566211" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Delandistrogene Moxeparvovec: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37566211" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Delandistrogene Moxeparvovec: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37497476" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37154743" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36806515" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Meeting Report: 2022 Muscular Dystrophy Association Summit on 'Safety and Challenges in Gene Transfer Therapy'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37754285" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707981" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Beneficial effects of creatine supplementation in dystrophic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10802796" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23740606" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Creatine for treating muscle disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159476" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15984021" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12447939" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Loss of myostatin attenuates severity of muscular dystrophy in mdx mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12459784" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Functional improvement of dystrophic muscle by myostatin blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215484" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Myostatin mutation associated with gross muscle hypertrophy in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215479" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Powerful genes--myostatin regulation of human muscle mass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18335515" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27462804" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32773450" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The elusive promise of myostatin inhibition for muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29478899" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Exosome-Mediated Benefits of Cell Therapy in Mouse and Human Models of Duchenne Muscular Dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30944252" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35279258" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9288722" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The fate of individual myoblasts after transplantation into muscles of DMD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12235112" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10517639" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Dystrophin expression in the mdx mouse restored by stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15038390" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18614009" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18815403" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Cell therapies for muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32619494" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Induced Fetal Human Muscle Stem Cells with High Therapeutic Potential in a Mouse Muscular Dystrophy Model.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
